Результаты поиска

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.

BackgroundThe optimal iron therapy regimen in patients with non-dialysis-dependent chronic kidney disease (CKD) is unknown.MethodsFerinject® assessment in patients with Iron deficiency anaemia and Non-Dialysis-dependent Chronic Kidney Disease (FIND-CKD) was a 56-week, open-label, multicentre, prospective and randomized study of 626 patients with non-dialysis-dependent CKD, anaemia and iron deficiency not receiving erythropoiesis-stimulating agents (ESAs). Patients were randomized (1:1:2) to intravenous (IV) ferric carboxymaltose (FCM), targeting a higher (400-600 µg/L) or lower (100-200 µg/L)

ANCA-Associated Glomerulonephritis: Diagnosis and Therapy Proceedings of the Henry Shavelle Lectureship.

BackgroundAnti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) frequently affects the kidney. Glomerulonephritis (GN) in AAV, ANCA-GN, not only dictates therapeutic decisions but is also of relevance for overall survival influencing the risk of cardiovascular disease and serious infections.SummaryA diagnosis of ANCA-GN includes laboratory investigations including urinalysis and a thorough assessment of potential organ involvement. A kidney biopsy can be performed to ascertain the diagnosis but has an additional prognostic relevance and tools have been established to predict

Отношение неврологов к тестированию серума на нейрофильтроустойчивость с использованием светоизлучающих склерозов при когнитивном повреждении.

Фон: Когнитивное расстройство влияет на функцию и качество жизни пациентов с множественным склерозом (МС). Уровни световых цепей с высоким сывороткой нейрофильтрации (SNfL) предсказывают прогрессию заболеваний, а также связаны с нарушениями когнитивных характеристик. Цель этого исследования заключалась в оценке отношения неюрологов к тестированию SNfL в том, что касается принятия терапевтических решений у клинических и радиологически стабильных пациентов, испытывающих когнитивный упадок. Методы: Было проведено исследование с использованием Интернета для наблюдения за неврологами, обеспечивающи

Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody.

Teclistamab is a BCMAxCD3 bispecific antibody, the first approved for the treatment of relapsed or refractory multiple myeloma. Given its impressive efficacy in heavily pretreated patients and better accessibility compared to BCMA-directed CAR T cells, teclistamab is sure to become a staple of relapsed/refractory multiple myeloma therapy. Teclistamab carries a set of notable adverse effects including cytokine release syndrome (CRS), infections, and neurotoxicity for which providers must take unique precautions and prophylactic measures. Here, we review the preclinical and clinical data, which

Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies.

As bispecific T-cell engagers (TCEs) gain traction in the oncology treatment landscape, cancer centres must develop robust clinical pathways to ensure their safe and efficient delivery. Given the limited experience of the Canadian medical oncology community with TCEs, collecting and publishing early clinical experiences with these novel agents will be essential to inform best practices and support their safe and effective adoption across the broader Canadian oncology community. The approval of tarlatamab, the first-in-class delta-like ligand 3 (DLL3)-targeted TCE for extensive-stage small cell

Уточнение роли селинксора в множестве миеломы: стратегическое использование в изменяющемся ландшафте обработки.

Площадь лечения множественной миеломы (ММ) революционизировалась в прошлом two десятилетиями, приводящими к беспрецедентным глубоким и долговременным ответным мерам, продолжительному выживанию и улучшению качества жизни. Тем не менее ММ по-прежнему является неизлечимым заболеванием, и многие пациенты, особенно больные цитогенетическими заболеваниями высокого риска, почечными расстройствами или ранней резистентностью к лекарственным препаратам, по-прежнему сталкиваются с плохими последствиями. Селинксор, первый в классе, в устной форме биодоступный селективный ингибитор экспорта 1 (XPO1) продем

Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy.

BACKGROUND: Although some cancer immunotherapies have been linked to increased cardiovascular risk, data on T-cell engager (TCE) therapy-associated cardiovascular complications remain limited. OBJECTIVES: This study sought to characterize the incidence and factors associated with cardiovascular events (CVEs) and mortality during TCE therapy. METHODS: We conducted a dual-center retrospective study of patients with cancer treated with TCEs between 2016 and 2024. The cumulative incidence of on-treatment CVEs (heart failure, arrhythmias, myocardial infarction, stroke) and cardiovascular mortalit

Feasibility and Impact of Adapted Physical Activity (APA) in Cancer Outpatients Beginning Medical Anti-Tumoral Treatment: The UMA-CHAPA Study.

Adapted physical activity (APA) improves quality of life and cancer outcomes. The aim of this study was to assess the feasibility of an APA program in outpatients beginning medical anticancer treatment. The secondary objective was to assess the impact of APA on fatigue, anxiety, depression, and handgrip strength (HGS). This prospective study was conducted between January and July 2017. Among 226 patients beginning treatment in the unit for a digestive, lung, hematological, or dermatological cancer, 163 were included. Adherence to the APA program was defined as more than or equal to one one-hou

Daratumumab плюс VRd в японских пациентах, имеющих право на трансплантацию/отсроченные заболевания NDMM: японская подгруппа по испытанию CEPHEUS.

:: фазы 3 Судебное разбирательство по делу CEPHEUS было проведено в 13 начиная с декабря 11, 2018 в случае пациентов с недавно поставленным диагнозом множественной миеломы (НДММ), которые имели право на трансплантацию или для которых трансплантация не была запланирована в качестве первоначальной терапии. Бортезомиб, линалидомид и дексаметасон (VRd) с даратумумабом (D-VRd) дали более глубокие и долгосрочные ответные меры и снизили риск развития заболеваний или смерти по сравнению с VRd. В ходе этого анализа была проведена оценка эффективности и безопасности D-VRd, в частности в японском поднасе

Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.

IntroductionPatients with triple-class exposed relapsed/refractory multiple myeloma (RRMM) have poor outcomes with substantial healthcare costs. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy, showed deep, durable responses in patients with RRMM in the pivotal phase 2 KarMMa trial (NCT03361748). Healthcare resource utilization (HCRU) and costs were estimated for ide-cel-treated patients in the KarMMa trial.MethodsPost-infusion costs were estimated based on HCRU data, including facility care, diagnostics, medications,

Совпадение в полном тексте источника
… Diagnostic, transfusion, and procedure costs were taken from the Centers for Medicare & Medicaid Services Clinical Laboratory and Physician Fee Schedules ( www.cms.gov/medicare/medicare ) and the Hospital Outpatient Prospective Payment System ( www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps …

Impact of frailty on mortality and quality of life in patients with a history of cancer undergoing transcatheter aortic valve replacement.

BackgroundTranscatheter aortic valve replacement (TAVR) is increasingly offered for aortic stenosis (AS) treatment in patients with a history of cancer. The impact of frailty on outcomes in this specific patient population is not well described.HypothesisFrailty is associated with mortality and poorer quality of life (QOL) outcomes in patients undergoing TAVR with a history of cancer.MethodsThis retrospective single center cohort study included AS patients who underwent TAVR from August 1, 2012 to May 15, 2020. Frailty was measured using serum albumin, hemoglobin, gait speed, functional depend

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).

The antiretroviral agent nelfinavir has antimyeloma activity and can overcome resistance to bortezomib. Our phase I/II trial investigated whether adding nelfinavir to lenalidomide-dexamethasone can overcome lenalidomide resistance in lenalidomide-refractory multiple myeloma (MM). Twenty-nine patients were included (high-risk cytogenetic aberrations 31%; ≥2 prior therapy lines 93%; lenalidomide-bortezomib double-refractory 34%). Twenty-four patients (83%) had prior bortezomib and 10 (34%) were lenalidomide-bortezomib double-refractory. They received four cycles of nelfinavir 2500 mg/day with st

Селективное истощение клеток В лежит в основе повышенного риска инфицирования у пациентов с лечением MM с помощью антиBCMA против S. anti-GPRC5D bsAbs.

При лечении пациентов с множественной миеломой (ММ) с антиклектовой антигенной зрелостью (BCMA) и антиG-белковой группой рецепторов C по-прежнему возникают проблемы. 5 - член D (GPRC5D) - двойные антитела (bsAbs). Вместе с тем механизм, лежащий в основе различных уровней и тяжести инфекций, вызванных 2 bSABs по-прежнему плохо понимаются. Секвенная последовательность последовательности КНН костного мозга (БМ) 11 пациентов с ММ и 8 Здоровые доноры обнаружили выражение BCMA на зрелых клетках B и, что удивительно, в небольших клетках до B в прекурсорах B-клеток. Выражение GPRC5D ограничивалось зло

Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

New reporting items and recommendations for randomized trials impacted by COVID-19 and force majeure events: a targeted approach.

BackgroundAppropriate analyses and reporting are essential to the reproducibility and interpretation of clinical trials. However, the coronavirus disease 19 (COVID-19) pandemic and other force majeure events, like the war in Ukraine, have impacted the conduct of clinical trials.MethodsThe number of clinical trials potentially impacted were estimated from clinicaltrials.gov. To identify reporting items considered vital for assessing the impact of COVID-19, we reviewed 35 randomized phase III trials from three top oncology journals published between July and December 2020. For validation, we rev

Оценка связанных с администрацией реакций с подкожной ДАТРАТУМАБ с прелестным лечением и без него.

Для лечения расстройств плазменных клеток часто используется фон Daratumumab-hyaluronidase-fihj (Dara-SQ), что связано с улучшением исхода. Было установлено, что " Dara-SQ " не является следствием инъекции " daratumumab " ( " Dara-IV " ) с точки зрения эффективности, безопасности и сопряжена с меньшим числом ответных мер, связанных с администрацией (АРР). Несмотря на более низкий риск АРВ в случае с Dara-SQ, маркировка пакетов по-прежнему рекомендует неопределённую предлежащую аптечку. В этом исследовании мы изучили вопрос о безопасности пренебрежения после того,

Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial.

Cryoprevention (CP) using ice (IC) is an effective strategy to prevent chemotherapy-induced oral mucositis (OM). However, the use of IC may cause adverse reactions and requires water of safe quality to minimize risk of serious infections. This randomized, blinded, parallel group, phase 3 trial was conducted in five Scandinavian centers. Eligible patients were diagnosed with multiple myeloma or lymphoma, scheduled to receive conditioning with high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation (ASCT). Patients were assigned to cooling with IC or a novel intraoral

Less is more: inverting the paradigm across the cancer care continuum.

Cancer care often operates under the assumption that 'more is better', resulting in frequent testing, intensive treatments, and constant follow-up. However, this approach has unintended consequences and places significant burdens on patients, providers, and healthcare systems. At the same time, cancer care is evolving rapidly and the number of cancer survivors continues to grow, highlighting the urgent need for reform.In the Netherlands, important efforts are taking place to de-escalate and de-implement ineffective practices across the cancer care continuum, from screening to palliative care.

:: Ранняя смертность, связанная с дивидендной антителной терапией, в рамках RRMM: Иммунотерапевтическая база данных ММРГ, анализ реального мира.

Совершенствование методов лечения, в том числе биконкретных антител (bsAbs), позволило улучшить результаты для пациентов с повторной/охлажденной множественной миеломой (RRMM). Однако ранняя смертность (РМС) остается серьезной проблемой даже в эпоху новой иммунотерапии. Мы провели многоцентральный ретроспективный анализ пациентов в реальном мире, при этом RRM были обработаны коммерческими бсабами для оценки частотности и причин ЭМ. В период с мая 2022 и июнь 2025, всего 441 пациентов лечили по всему району 7 странами. EM, определяемый как смерть внутри 12 месяцев начала терапии, 148 (больные)34

Sex Differences in Cancer and Cardiotoxicity: Mechanisms, Outcomes, and Clinical Implications Across Solid and Hematological Malignancies.

Sex differences influence cancer incidence, treatment response, and susceptibility to cardiovascular toxicity. Males exhibit higher rates and poorer outcomes in most non-sex-specific cancers, while females more frequently experience treatment-related adverse events, including cancer therapy-related cardiac dysfunction. Biological factors such as hormonal status, genetic polymorphisms, immune responses, and pharmacokinetics contribute to these disparities. In cardio-oncology, women-particularly premenopausal or with specific genotypes-may be at increased risk for cardiotoxicity after treatment